CytoDyn requests Fast Track Approval in U.K. for COVID-19 trial

CytoDyn (OTCQB:CYDY) has provided its top-line report from its recently completed Phase 2 clinical trial for patients with mild-to-moderate COVID-19 symptoms to regulatory authorities in U.K.

The Company has requested for the regulatory pathway for Fast Track approval noting the efficacy and safety results from the Phase 2 trial.

“We are eager to see the capabilities of leronlimab in our Phase 3 clinical trial for the severe-to-critical patient population. Our enrollment is now at 182 and we are very optimistic we will reach 195 by the end of August,” stated Nader Pourhassan, Ph.D., President and CEO.

Previously: CytoDyn announces “positive” results from mid-stage COVID-19 study (Aug. 11)

https://seekingalpha.com/news/3606919-cytodyn-requests-fast-track-approval-in-u-k-for-covidminus-19-trial